Bipolar Depression Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight

Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, Bipolar Depression pipeline constitutes 8+ key companies continuously working towards developing 10+ Bipolar Depression treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Bipolar Depression Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Bipolar Depression Market.

The Bipolar Depression Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Bipolar Depression Pipeline Report: https://www.delveinsight.com/sample-request/bipolar-depression-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Bipolar Depression treatment therapies with a considerable amount of success over the years.
• Bipolar Depression Key players such as - Autobahn Therapeutics, Allergan (AbbVie)/Gedeon Richter, Alkermes, Glaxo SmithKline (GSK), ELI Lilly and Company, Janssen Pharmaceuticals, Astellas Pharma Inc., Bristol Myers Squibb, Gedeon Richter Plc., H. Lundbeck A/S, Pfizer Inc., Novartis AG, Otsuka Holdings Co. Ltd, Validus Pharmaceuticals LLC, NeuroRx, Sunovion (Sumitomo Dainippon Pharma), COMPASS Pathways, SAGE Therapeutics, Forest Laboratories, Target Health Inc., Vanguard, Inc., AstraZeneca, Celon Pharma SA, Intra-Cellular Therapies, Inc., Arvid Carlsson Research AB, Solvay Pharmaceuticals, Shire, Intra-Cellular Therapies, Inc., and others, are developing therapies for the Bipolar Depression treatment
• Bipolar Depression Emerging therapies such as - ABX-002, VRAYLAR (Cariprazine), LYBALVI (olanzapine, samidorphan L-malate), NRX-100, NRX-101, SEP-4199, COMP 360 (Psilocybin Therapy), Sage-217, cariprazine, Ketamine Hydrochloride, Lurasidone HCl, Quetiapine Fumarate (SEROQUEL), Esketamine, Lumateperone, Brexpiprazole, OSU6162, Bifeprunox, carbamazepine ER, ITI-007 (Lumateperone), Olanzapine Fluoxetine Combination (OFC), lamotrigine, FK949E, SM-13496, and others are expected to have a significant impact on the Bipolar Depression market in the coming years.
• In January 2025, Autobahn Therapeutics, a biotech company focused on developing restorative therapies for neuropsychiatric and neuroimmunologic disorders, has initiated a Phase 2 clinical trial for ABX-002, a potent oral thyroid hormone beta receptor (TRβ) selective agonist, as an adjunctive treatment for bipolar depression in adults. This trial aims to establish both biological and clinical proof-of-concept, guiding the company's future clinical development strategy.
• In April 2024, NRx Pharmaceuticals announced encouraging results from its Phase IIb/III clinical trial comparing NRX-101 to lurasidone for treating suicidal bipolar depression. The findings showed a promising, though not yet statistically significant, 33% reduction in suicidality, along with a 70% reduction in akathisia symptoms (P=.076).

Bipolar Depression Overview
Bipolar disorder is a disabling chronic disease in which depression usually presents a higher risk of long-term functional impairment than mania. Persistent depression does not have a known cause. As with bipolar disorder, depression has hereditary factors and might also involve neurotransmitter imbalances in the brain.

Get a Free Sample PDF Report to know more about Bipolar Depression Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/bipolar-depression-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Bipolar Depression Drugs Under Different Phases of Clinical Development Include:
• ABX-002: Autobahn Therapeutics
• VRAYLAR (Cariprazine): Allergan (AbbVie)/Gedeon Richter
• LYBALVI (olanzapine, samidorphan L-malate): Alkermes
• NRX-100/ NRX-101: NeuroRx
• SEP-4199: Sunovion (Sumitomo Dainippon Pharma)
• COMP 360 (Psilocybin Therapy): COMPASS Pathways
• Sage-217: SAGE Therapeutics
• cariprazine: Forest Laboratories
• Ketamine Hydrochloride: Target Health Inc.
• Lurasidone HCl: Vanguard, Inc.
• Quetiapine Fumarate (SEROQUEL): AstraZeneca
• Esketamine: Celon Pharma SA
• Lumateperone: Intra-Cellular Therapies, Inc.
• Brexpiprazole: Otsuka America Pharmaceutical
• OSU6162: Arvid Carlsson Research AB
• Bifeprunox: Solvay Pharmaceuticals
• carbamazepine ER: Shire
• ITI-007 (Lumateperone): Intra-Cellular Therapies, Inc.
• Olanzapine Fluoxetine Combination (OFC): Eli Lilly and Company
• lamotrigine: GlaxoSmithKline
• FK949E: Astellas Pharma Inc
• SM-13496: Sumitomo Pharma Co., Ltd.

Route of Administration
Bipolar Depression pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical

Molecule Type
Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Bipolar Depression Pipeline Therapeutics Assessment
• Bipolar Depression Assessment by Product Type
• Bipolar Depression By Stage and Product Type
• Bipolar Depression Assessment by Route of Administration
• Bipolar Depression By Stage and Route of Administration
• Bipolar Depression Assessment by Molecule Type
• Bipolar Depression by Stage and Molecule Type

DelveInsight's Bipolar Depression Report covers around 10+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Some of the key companies in the Bipolar Depression Therapeutics Market include:
Key companies developing therapies for Bipolar Depression are - Allergan (AbbVie)/Gedeon Richter, Sunovion Pharmaceuticals (Sumitomo Dainippon Pharma), Intra-Cellular Therapies, NeuroRx, Sunovion (Sumitomo Dainippon Pharma), Lundbeck/Otsuka Pharmaceutical, Celon Pharma, COMPASS Pathways and others

Bipolar Depression Pipeline Analysis:
The Bipolar Depression pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Bipolar Depression with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Bipolar Depression Treatment.
• Bipolar Depression key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Bipolar Depression Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Bipolar Depression market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Bipolar Depression product details are provided in the report. Download the Bipolar Depression pipeline report to learn more about the emerging Bipolar Depression therapies
https://www.delveinsight.com/report-store/bipolar-depression-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Bipolar Depression Pipeline Market Drivers
• Demand of new technologies
• Increase in the awareness regarding mental disorders

Bipolar Depression Pipeline Market Barriers
• Fewer randomized controlled trials (RCTs) of acute Bipolar Depression
• Strict pricing and reimbursement policies

Scope of Bipolar Depression Pipeline Drug Insight
• Coverage: Global
• Key Bipolar Depression Companies: Autobahn Therapeutics, Allergan (AbbVie)/Gedeon Richter, Alkermes, Glaxo SmithKline (GSK), ELI Lilly and Company, Janssen Pharmaceuticals, Astellas Pharma Inc., Bristol Myers Squibb, Gedeon Richter Plc., H. Lundbeck A/S, Pfizer Inc., Novartis AG, Otsuka Holdings Co. Ltd, Validus Pharmaceuticals LLC, NeuroRx, Sunovion (Sumitomo Dainippon Pharma), COMPASS Pathways, SAGE Therapeutics, Forest Laboratories, Target Health Inc., Vanguard, Inc., AstraZeneca, Celon Pharma SA, Intra-Cellular Therapies, Inc., Arvid Carlsson Research AB, Solvay Pharmaceuticals, Shire, Intra-Cellular Therapies, Inc., and others
• Key Bipolar Depression Therapies: ABX-002, VRAYLAR (Cariprazine), LYBALVI (olanzapine, samidorphan L-malate), NRX-100, NRX-101, SEP-4199, COMP 360 (Psilocybin Therapy), Sage-217, cariprazine, Ketamine Hydrochloride, Lurasidone HCl, Quetiapine Fumarate (SEROQUEL), Esketamine, Lumateperone, Brexpiprazole, OSU6162, Bifeprunox, carbamazepine ER, ITI-007 (Lumateperone), Olanzapine Fluoxetine Combination (OFC), lamotrigine, FK949E, SM-13496, and others
• Bipolar Depression Therapeutic Assessment: Bipolar Depression current marketed and Bipolar Depression emerging therapies
• Bipolar Depression Market Dynamics: Bipolar Depression market drivers and Bipolar Depression market barriers

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.